Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 8, 2024

(2) APPOINTMENT OF DIRECTORS OF THE SECOND SESSION OF THE BOARD AND DEPARTURE OF DIRECTOR (3) APPOINTMENT OF NON-EMPLOYEE REPRESENTATIVE SUPERVISORS OF THE SECOND SESSION OF THE SUPERVISORY BOARD

- (4) ELECTION OF THE CHAIRMAN OF THE SECOND SESSION OF THE BOARD AND MEMBERS OF SPECIAL COMMITTEES
- (5) ELECTION OF THE CHAIRWOMAN OF THE SECOND SESSION OF THE SUPERVISORY BOARD

AND

(6) RE-APPOINTMENT OF GENERAL MANAGER

References are made to the notice of annual general meeting (the "AGM Notice") and the circular (the "Circular") of Jiangsu Recbio Technology Co., Ltd. (the "Company") both dated April 17, 2024. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the AGM Notice and the Circular.

The AGM was held at 10:00 a.m. on Wednesday, May 8, 2024 at Conference Room, 3/F, Building G29, Standard Plant, China Medical City Phase 6, Medical High-tech District, Taizhou City, Jiangsu Province, the PRC. All of the Directors attended the AGM.

As at the date of the AGM, the total number of issued Shares of the Company was 482,963,000, comprising 154,824,311 Domestic Shares, 12,000,000 Unlisted Foreign Shares and 316,138,689 H Shares, which was the total number of Shares entitling the holders to attend and vote on the resolutions proposed at the AGM. No Shareholders were required under the Listing Rules to abstain from voting on the resolutions. There were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM. The convening of the AGM was in compliance with the relevant requirements of the Company Law and the Articles of Association.

Shareholders and duly authorized proxies, holding a total of 194,067,152 Shares, representing approximately 40.1826% of the total number of issued Shares, were present at the AGM. The resolutions at the AGM were put to vote by way of poll.

POLL RESULTS OF THE AGM

The Board is pleased to announce that the following resolutions (special resolution marked with *) have been duly passed at the AGM and the details of the poll results are set out as follows:

		DEGOT MANONG	NUMBER OF VOTES (%)			
		RESOLUTIONS		AGAINST	ABSTAIN	
1.		consider and approve the Resolution on 2023 ncial Accounts Report of the Company	191,374,845 100%	0 0%	0 0%	
2.		consider and approve the Resolution on 2024 ncial Budget Report of the Company	191,374,845 100%	0 0%	0 0%	
3.	1	consider and approve the Resolution on 2023 Work ort of the Board of Directors of the Company	191,374,845 100%	0 0%	0 0%	
4.	1	onsider and approve the Resolution on 2023 Annual ort of the Company	191,374,845 100%	0 0%	0 0%	
5.		consider and approve the Resolution on 2023 Work ort of the Supervisory Board of the Company	191,374,845 100%	0 0%	0 0%	
6.		To consider and approve the Resolution on Engagement of Auditors of the Company for 2024		0 0%	0 0%	
7.	Rem	consider and approve the Resolution on 2024 uneration Scheme for Directors and Supervisors of Company	191,374,845 100%	0 0%	0 0%	
8.		consider and approve the Resolution on 2023 Profit ribution Plan of the Company	191,374,845 100%	0 0%	0 0%	
9.	To consider and approve the Resolution on Election of Non-independent Directors of the Second Session of the Board:					
	9.1	To consider and approve the Election of Dr. LIU Yong as an Executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	
	9.2	To consider and approve the Election of Mr. LI Bu as an Executive Director of the Second Session of the Board		0 0%	0 0%	
	9.3	To consider and approve the Election of Ms. CHEN Qingqing as an Executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	
	9.4	To consider and approve the Election of Dr. HONG Kunxue as an Executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	
	9.5	To consider and approve the Election of Dr. WANG Ruwei as a Non-executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	

	DEGOV VIEWOVA		NUMBER OF VOTES (%)			
		RESOLUTIONS	FOR	AGAINST	ABSTAIN	
	9.6	To consider and approve the Election of Dr. ZHANG Jiaxin as a Non-executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	
	9.7	To consider and approve the Election of Dr. ZHOU Hongbin as a Non-executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	
	9.8	To consider and approve the Election of Mr. HU Houwei as a Non-executive Director of the Second Session of the Board	191,374,845 100%	0 0%	0 0%	
10.	To consider and approve the Resolution on Election of Independent Directors of the Second Session of the Board:					
	10.1	To consider and approve the Election of Dr. XIA Lijun as an Independent Non-executive Director of the Second Session of the Board	194,067,152 100%	0 0%	0 0%	
	10.2	To consider and approve the Election of Mr. LIANG Guodong as an Independent Non-executive Director of the Second Session of the Board	194,067,152 100%	0 0%	0 0%	
	10.3	To consider and approve the Election of Professor GAO Feng as an Independent Non-executive Director of the Second Session of the Board	194,067,152 100%	0 0%	0 0%	
	10.4	To consider and approve the Election of Professor YUEN Ming Fai as an Independent Non-executive Director of the Second Session of the Board	194,067,152 100%	0 0%	0 0%	
1.	To consider and approve the Resolution on Election of Non-employee Representative Supervisors of the Second Session of the Supervisory Board:					
	11.1	To consider and approve the Election of Ms. QIAN Ranting as a Non-employee Representative Supervisor of the Second Session of the Supervisory Board	194,067,152 100%	0 0%	0 0%	
	11.2	To consider and approve the Election of Mr. WANG Feizhou as a Non-employee Representative Supervisor of the Second Session of the Supervisory Board	194,067,152 100%	0 0%	0 0%	
2.	Gene	consider and approve the Resolution on Grant of eral Mandate to the Board to Issue Additional Shares e Company	191,373,345 99.9992%	1,500 0.0008%	0 0%	

As more than half of the votes were cast in favor of each of the resolutions numbered 1 to 11, these resolutions were duly passed as ordinary resolutions of the Company. As more than two thirds of the votes were cast in favor of the resolution numbered 12, the resolution was duly passed as a special resolution of the Company.

The Company's H Share Registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, two Shareholder representatives and one Supervisor representative of the Company were appointed as the scrutineers for the purpose of vote-taking at the AGM.

APPOINTMENT OF DIRECTORS OF THE SECOND SESSION OF THE BOARD AND DEPARTURE OF DIRECTOR

The Board is pleased to announce that at the AGM, (i) Dr. LIU Yong, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue were appointed as executive Directors of the second session of the Board; (ii) Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei were appointed as non-executive Directors of the second session of the Board; and (iii) Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai were appointed as independent non-executive Directors of the second session of the Board. The biographies of the above appointed Directors and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out in the Circular. As of the date of this announcement, such information has no change.

Following the formation of the second session of the Board of the Company, Dr. CHEN Jianping, an executive Director of the first session of the Board of the Company, ceased to be an executive Director of the Company with effect from May 8, 2024 due to the expiry of his term of office. Dr. CHEN has confirmed that he has no disagreement with the Company and the Board, and there are no other matters relating to his departure that need to be brought to the attention of the Stock Exchange and the Shareholders. The Company would like to take this opportunity to express its sincere gratitude to Dr. CHEN for his contributions to the development of the Company during his tenure.

APPOINTMENT OF NON-EMPLOYEE REPRESENTATIVE SUPERVISORS OF THE SECOND SESSION OF THE SUPERVISORY BOARD

The Board is pleased to announce that, Ms. QIAN Ranting and Mr. WANG Feizhou have been appointed as the non-employee representative Supervisors of the second session of the Supervisory Board of the Company at the AGM. The biographies of Ms. QIAN Ranting and Mr. WANG Feizhou and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out in the Circular. As of the date of this announcement, such information has no change.

ELECTION OF THE CHAIRMAN OF THE SECOND SESSION OF THE BOARD AND MEMBERS OF SPECIAL COMMITTEES

On May 8, 2024, the Board held a meeting of the Board, at which (i) Dr. LIU Yong was elected as the Chairman of the second session of the Board of the Company, which shall take effect from the date of the consideration and approval by the Board, with a term of office of three years; (ii) Professor YUEN Ming Fai, Dr. XIA Lijun, Mr. LI Bu, Mr. LIANG Guodong, Professor GAO Feng were elected as members of the Remuneration and Appraisal Committee of the second session of the Board, with Professor YUEN Ming Fai acting as the chairman of the committee; (iii) Dr. XIA Lijun, Professor YUEN Ming Fai and Dr. ZHOU Hongbin were elected as members of the Audit Committee of the second session of the Board, with Dr. XIA Lijun acting as the chairman of the committee; and (iv) Dr. LIU Yong, Dr. XIA Lijun, Mr. LIANG Guodong and Professor GAO Feng were elected as members of the Nomination Committee of the second session of the Board, with Dr. LIU Yong acting as the chairman of the committee. Terms of office of above members of the special committees of the Board shall be consistent with that of the Board and take effect from the date of the consideration and approval by the Board.

ELECTION OF THE CHAIRWOMAN OF THE SECOND SESSION OF THE SUPERVISORY BOARD

The Supervisory Board held a Supervisory Board meeting on May 8, 2024, at which Ms. QIAO Weiwei has been appointed as the Chairwoman of the second session of the Supervisory Board of the Company. The biography of Ms. QIAO is set out in the announcement of the Company dated May 7, 2024. Save as disclosed therein, the Board is not aware of other information on Ms. QIAO which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to Ms. QIAO that need to be brought to the attention of the Shareholders.

RE-APPOINTMENT OF GENERAL MANAGER

As Dr. LIU Yong's term of office as the general manager of the Company shall expire in May 2024, the Board re-appointed Dr. LIU Yong as the general manager of the Company at the Board meeting held on May 8, 2024, which shall take effect from the date of the consideration and approval by the Board, with a term of office of three years. The biographies of Dr. LIU and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out in the Circular. As of the date of this announcement, such information has no change. Save as disclosed in this announcement, the Board is not aware of other information on the the re-appointment of Dr. LIU as the general manager which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the re-appointment of Dr. LIU as the general manager that need to be brought to the attention of the Shareholders.

Under Code Provision C.2.1 of the Corporate Governance Code contained in Appendix C1 to the Listing Rules, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. In view of Dr. LIU's experience, personal profile and his roles in our Company and that Dr. LIU has assumed the role of general manager of our Company since our commencement of business, the Board considers it beneficial to the business prospect and operational efficiency of our Company that Dr. LIU acts as the chairman of the Board and continues to act as the general manager of our Company.

While this will constitute a deviation from the code provision, the Board believes that this structure will not impair the balance of power and authority between the Board and the management of our Company, given that: (i) any decision to be made by our Board requires approval by at least a majority of our Directors; (ii) Dr. LIU and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that they act for the benefits and in the best interests of our Company and will make decisions for our Company accordingly; and (iii) the balance of power and authority is ensured by the operations of the Board which comprises experienced and high caliber individuals who meet regularly to discuss issues affecting the operations of our Company. Moreover, the overall strategic and other key business, financial, and operational policies of our Company are made collectively after thorough discussions by both the Board and senior management. The Board will continue to review the effectiveness of the corporate governance structure of our Company in order to assess whether separation of the roles of chairman of the Board and chief executive officer is necessary.

By order of the Board

Jiangsu Recbio Technology Co., Ltd.

Dr. LIU Yong

Chairman

Jiangsu Province, the PRC, May 8, 2024

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive Directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive Directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.